Literature DB >> 19258681

Prevention and management of coronary artery disease in patients with diabetes mellitus.

Abdul Majid1.   

Abstract

Diabetes mellitus (DM) is a common medical problem and a major risk factor for the development of atherosclerotic coronary artery disease (CAD). Coronary artery disease is highly prevalent and is the major cause of morbidity and mortality in diabetic patients. Patients with CAD and prediabetic states should undergo lifestyle modifications aimed at preventing DM. In patients with CAD and DM, routine use of aspirin and an angiotensin-converting enzyme inhibitor (ACE-I)-unless contraindicated or not tolerated-and strict glycemic, blood pressure, and lipid control are strongly recommended. Intense insulin therapy might be needed for glycemic control, and high-dose statin therapy might be needed for lipid control. For blood pressure control, ACE-Is and angiotensin receptor blockers are considered as first-line therapy. The outcomes after revascularization in diabetic patients are usually worse compared with non-diabetic patients. Advances in PCI include the use of drug-eluting stents and adjunctive drug therapies, such as abciximab. Glycemic control is an important determinant of outcome after revascularization in diabetic patients. Improvements in PCI and coronary artery bypass graft surgery are leading to better results in diabetic patients, and clinical trials are presently comparing contemporary PCI with surgery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19258681

Source DB:  PubMed          Journal:  Acta Med Indones        ISSN: 0125-9326


  1 in total

1.  Interleukin-1/toll-like receptor-induced nuclear factor kappa B signaling participates in intima hyperplasia after carotid artery balloon injury in goto-kakizaki rats: a potential target therapy pathway.

Authors:  Xiaotian Zhang; Yi Wang; Wenjing Hu; Dongye Li; Zhongmin Zhou; Defeng Pan; Wanling Wu; Tongda Xu
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.